Equity Profile

BCRX

BioCryst Pharmaceuticals, Inc.

Health CareBiotechnology$2.5B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.23

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$183M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $3 billion, it operates in the health care sector, which is currently seeing increased interest due to advancements in drug development and personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an unexpected loss with an EPS of $-2.98, significantly missing analyst expectations. The stock reacted negatively, dropping 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about BioCryst's upcoming earnings, expecting a rebound in EPS and revenue after a disappointing last quarter. The consensus estimates suggest improvement, but the company has a mixed earnings history.

Bull Case

If BioCryst can meet or exceed the consensus estimates, it could signal a turnaround in financial performance and boost investor confidence, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its growth prospects and lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.23

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$183M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioCryst report an EPS of at least $0.23?

This figure is crucial as it reflects the company's ability to recover from previous losses and meet market expectations.

What revenue figure will BioCryst report, and how does it compare to the $183M consensus?

Revenue performance is a key indicator of market demand for BioCryst's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for BioCryst to rebound from its last quarter's performance, as the company has a history of surprising analysts positively.

Supporting Evidence

BioCryst has beaten EPS estimates 63% of the time in the past eight quarters.

The options market is pricing a larger move than the historical average, indicating potential for volatility.

Recent earnings history shows significant positive surprises following negative quarters.

Key Risk

If BioCryst's revenue comes in above $235M, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioCryst can sustain its recovery or if it will continue to struggle.

Bull Confirmed If

An EPS of $0.23 or better, along with revenue exceeding $183M, would confirm a positive turnaround narrative.

Bear Confirmed If

An EPS below $0.08 or revenue below $160M would reinforce concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by about 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should the company miss estimates, the stock could drop by around 8.34%, indicating ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market demand for existing treatments.
3Insights into cost management strategies and their effect on profitability.
4Discussion of any new partnerships or collaborations that may enhance growth.
5Clarification on guidance for the next quarter and full year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.23

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$183M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an unexpected loss with an EPS of $-2.98, significantly missing analyst expectations. The stock reacted negatively, dropping 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioCryst can meet or exceed the consensus estimates, it could signal a turnaround in financial performance and boost investor confidence, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its growth prospects and lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.23

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$183M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioCryst report an EPS of at least $0.23?

This figure is crucial as it reflects the company's ability to recover from previous losses and meet market expectations.

What revenue figure will BioCryst report, and how does it compare to the $183M consensus?

Revenue performance is a key indicator of market demand for BioCryst's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for BioCryst to rebound from its last quarter's performance, as the company has a history of surprising analysts positively.

Supporting Evidence

BioCryst has beaten EPS estimates 63% of the time in the past eight quarters.

The options market is pricing a larger move than the historical average, indicating potential for volatility.

Recent earnings history shows significant positive surprises following negative quarters.

Key Risk

If BioCryst's revenue comes in above $235M, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether BioCryst can sustain its recovery or if it will continue to struggle.

Bull Confirmed If

An EPS of $0.23 or better, along with revenue exceeding $183M, would confirm a positive turnaround narrative.

Bear Confirmed If

An EPS below $0.08 or revenue below $160M would reinforce concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by about 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

Should the company miss estimates, the stock could drop by around 8.34%, indicating ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market demand for existing treatments.
3Insights into cost management strategies and their effect on profitability.
4Discussion of any new partnerships or collaborations that may enhance growth.
5Clarification on guidance for the next quarter and full year.